Merck enters into agreement to acquire Acceleron Pharma

Merck & Co. is in advanced talks to acquire Acceleron Pharma Inc., according to people familiar with the matter, in a move that would bolster the pharmaceutical giant’s rare disease business.

The deal for Acceleron, which has a market value of around $ 11 billion, could be announced this week, assuming the talks don’t collapse, people said.